Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2004

View Archived Issues

Specific protein kinase inhibitors with strong anticytomegaloviral activity

Progen Industries reviews 2004 highlights

TheraCIM hR3 awarded orphan drug status for glioma

GenVec licenses PEDF rights for ocular diseases

Treatment begins in phase II study of Albuferon plus ribavirin for hepatitis C

Enrollment completed in phase II study of HGS-ETR1 for NSCLC

RiVax, first ricin vaccine to enter human clinical trials

Phase II talabostat study in NSCLC advances to second stage

NPS to include two-year data in Preos NDA filing

IND filing for phase III study of Aridol for asthma

Estrogen analogues show neuroprotective, sex-independent effects in ischemic injury model

Retinoic acid metabolism blocking agents inhibit tumor growth in vivo

Clinical benefits found for infliximab, pimecrolimus in Behcet's disease / News in Context

Fenofibrate plus ezetimibe reported more effective than either drug alone in mixed hyperlipidemia

Myogen completes two pivotal clinical trials on enoximone in CHF

Cilnidipine for the treatment of arrhythmia

A new method for the treatment of Parkinson's disease claimed by Newron

Vertex scientists describe novel protein kinase inhibitors

Serotonin reuptake inhibitors for treatment of affective disorders claimed in Lundbeck patents

Antimitotic KSP kinesin inhibitors in early development at Merck

Tryptanthrin derivatives for treatment of highly proliferative diseases, such as leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...